PhaseV

growth-positive

PhaseV, a leader in AI/ML for clinical development, is set to participate in several biopharma conferences to showcase their expertise in next-generation Bayesian and causal AI. These technologies enhance the flexibility, robustness, and speed of clinical trials. The company aims to reduce risk and accelerate the path to market for sponsors. PhaseVs platform has significantly reduced trial costs and durations while increasing the probability of trial success. The company will present at various events, including the Pharma Tech Forum, ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Fierce Biotech Week, and Bayesian Biostatistics Conference. PhaseVs solutions are being leveraged by over 40 leading pharma/biotech sponsors and CROs across multiple therapeutic areas.

growth-positive

PhaseV has announced a strategic partnership with the Crohns & Colitis Foundation to advance research and development in inflammatory bowel disease (IBD) treatments. By leveraging the Foundations IBD Plexus® Research Accelerator and PhaseVs AI/ML solutions, the collaboration aims to overcome challenges in clinical development and enhance personalized treatment strategies. This partnership will help biopharma sponsors design more flexible, patient-centric trials, potentially leading to more effective IBD therapies. The collaboration reflects a commitment to addressing the complexities of IBD and improving patient outcomes through innovative trial designs and data-driven approaches.

growth-positive

PhaseV, an Israeli startup, has raised $50 million in a Series A funding round co-led by Accel and Insight Partners, with participation from Viola Ventures, EXOR, and LionBird. This brings the companys total funding to $65 million. PhaseV is leveraging artificial intelligence to enhance clinical trial design and execution, aiming to reduce the high costs and slow timelines traditionally associated with drug development. The company has already secured over 30 global customers, including major pharmaceutical firms, indicating strong demand for its AI-powered platform. PhaseVs approach focuses on a vertical AI platform tailored specifically for clinical research, offering features like adaptive trial design and real-time cohort optimization.

growth-positive

PhaseV, a startup founded less than two years ago, has successfully raised $50 million in a funding round led by prominent funds. The company serves dozens of pharmaceutical companies worldwide. PhaseV has developed technology that identifies why certain clinical trials fail, not because the drug is ineffective, but due to improper design or analysis. This investment is expected to further enhance their capabilities and expand their reach in the pharmaceutical industry.

growth-positive

PhaseV, a leader in AI/ML-driven clinical development, has raised $50 million in a Series A funding round co-led by Accel and Insight Partners, with participation from existing investors. The funding will support the expansion of PhaseVs vertical AI platform, which is already used by over 30 global pharma companies across more than 20 therapeutic areas. The platform has demonstrated significant reductions in trial costs and durations, and an increase in trial success rates. PhaseVs technology is poised to transform clinical development by optimizing trial design and execution, and the company plans to add more capabilities to its platform.